| Remotely Triggered Nano-Theranostics For Cancer Applications A Sneider, D VanDyke, S Paliwal, P Rai Nanotheranostics 1 (1), 1-22, 2017 | 104 | 2017 |
| Engineering Remotely Triggered Liposomes to Target Triple Negative Breast Cancer A Sneider, R Jadia, B Piel, D VanDyke, C Tsiros, P Rai Oncomedicine 2, 1-13, 2017 | 34 | 2017 |
| Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection D VanDyke, M Iglesias, J Tomala, A Young, J Smith, JA Perry, E Gebara, ... Cell Reports 41 (3), 111478, 2022 | 27 | 2022 |
| Nanoparticle Based Combination Treatments for Targeting Multiple Hallmarks of Cancer D VanDyke, P Kyriacopulos, B Yassini, A Wright, E Burkhart, S Jacek, ... International Journal of Nano Studies and Technology, 2016 | 24 | 2016 |
| Bioengineered particles expand myelin-specific regulatory T cells and reverse autoreactivity in a mouse model of multiple sclerosis KR Rhodes, SY Tzeng, M Iglesias, D Lee, K Storm, SY Neshat, ... Science Advances 9 (22), eadd8693, 2023 | 11 | 2023 |
| Biologics-based degraders—an expanding toolkit for targeted-protein degradation D VanDyke, JD Taylor, KJ Kaeo, J Hunt, JB Spangler Current opinion in biotechnology 78, 102807, 2022 | 9 | 2022 |
| Lung tumor–infiltrating Treg have divergent transcriptional profiles and function linked to checkpoint blockade response AG Dykema, J Zhang, LS Cheung, S Connor, B Zhang, Z Zeng, ... Science immunology 8 (87), eadg1487, 2023 | 8 | 2023 |
| A suspension cell‐based interaction platform for interrogation of membrane proteins PJ Krohl, KB Kim, L Lew, D VanDyke, SD Ludwig, JB Spangler AIChE Journal 66 (12), e16995, 2020 | 8 | 2020 |
| IL-2 can signal via chemokine receptors to promote regulatory T cells’ suppressive function H Sun, HS Lee, SHJ Kim, MF de Lima, AR Gingras, Q Du, W McLaughlin, ... Cell reports 42 (8), 2023 | 4 | 2023 |
| Discovery of antibodies targeting multipass transmembrane proteins using a suspension cell-based evolutionary approach PJ Krohl, J Fine, H Yang, D VanDyke, Z Ang, KB Kim, ... Cell Reports Methods 3 (3), 2023 | 2 | 2023 |
| Molecular engineering of Interleukin-2 for enhanced therapeutic activity in autoimmune diseases LM Tomasovic, K Liu, D VanDyke, CS Fabilane, JB Spangler Biodrugs 38 (2), 227-248, 2024 | 1 | 2024 |
| Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune … TK Kishimoto, M Fournier, A Michaud, G Rizzo, C Roy, T Capela, ... Journal of Autoimmunity 140, 103125, 2023 | 1 | 2023 |
| Synergistic activity of IL-2 mutein with tolerogenic ImmTOR nanoparticles leads to massive expansion of antigen-specific Tregs and protection against autoimmune disease TK Kishimoto, M Fournier, A Michaud, G Rizzo, C Roy, T Capela, ... bioRxiv, 2023.05. 15.540840, 2023 | 1 | 2023 |
| Tolerogenic Artificial Antigen Presenting Cells for Selective Tolerance in Autoimmune Disease G Raimondi, K Rhodes, S Tzeng, MI Lozano, D VanDyke, S Neshat, ... The Journal of Immunology 208 (1_Supplement), 60.18-60.18, 2022 | 1 | 2022 |
| Methods and materials for targeted expansion of regulatory t cells J Spangler, D VanDyke WO Patent WO2020264318A1, 2020 | 1 | 2020 |
| Innovative synthetic signaling technologies for immunotherapy D VanDyke, W Wang, JB Spangler Current Opinion in Biomedical Engineering 16, 1-8, 2020 | 1 | 2020 |
| Isolated cardiac myocytes of copper-deficient rats have altered dimensions and responses to osmotic stress. LJ Heller, D VanDyke, J Smith, B Brokate, JR Prohaska, A Becker FASEB JOURNAL 13 (5), A768-A768, 1999 | 1 | 1999 |
| Cytokine/Antibody Fusion Protein Design and Evaluation CS Fabilane, AC Stephenson, EK Leonard, D VanDyke, JB Spangler Current Protocols 4 (5), e1061, 2024 | | 2024 |
| Redirecting the specificity of tripartite motif containing-21 scaffolds using a novel discovery and design approach D VanDyke, L Xu, PR Sargunas, RN Gilbreth, M Baca, C Gao, J Hunt, ... Journal of Biological Chemistry 299 (12), 2023 | | 2023 |
| Augmenting the Persistence and Efficacy of Engineered Regulatory T Cells to Suppress Anti-Drug Antibody Formation J Rana, D VanDyke, M Munoz, SRP Kumar, M Gonzales, J Spangler, ... Blood 140 (Supplement 1), 7374-7375, 2022 | | 2022 |
